Quick Read
Procter & Gamble (PG) reported Q3 FY2026 Core EPS of $1.59, beating the $1.55 consensus, with revenue of $21.23B up 7.4% YoY and five consecutive earnings beats, while the stock trades 14% below its 52-week high despite delivering broad-based growth across all segments and regions.
PG trades at a discount despite fundamental strength due to tariff headwinds ($400M after-tax) and margin compression, but the companyโs Portfolio/Supply Chain Productivity Plan targets $1.5B in cost-of-goods-sold savings and 7,000 role reductions by end of FY2027, positioning it as a defensive cash machine with a 70-year dividend streak yielding 3%.
The analyst who called NVIDIA in 2010 just named his top 10 stocks and P&G wasn’t one of them. Get them here FREE.
Our 24/7 Wall St. price target for Procter & Gamble (NYSE:PG) is $163.50, implying a 14.95% upside from today’s price. Procter & Gamble trades at $142.24 as of May 13, 2026, with a $330.7 billion market cap and a beta of 0.4.
Our recommendation is buy, with 90% confidence. PG is a defensive cash machine trading well below recent highs, supported by analyst consensus and stable earnings power.
The analyst who called NVIDIA in 2010 just named his top 10 stocks and P&G wasn’t one of them. Get them here FREE.
Metric | Value |
|---|---|
Current Price | $142.24 |
24/7 Wall St. Price Target | $163.50 |
Upside | 14.95% |
Recommendation | BUY |
Confidence Level | 90% |
A Defensive Name That Sold Off Into Earnings Strength
PG is down 7.84% over 12 months, off 3.83% in the past week, and barely positive year to date at +0.69%. Shares sit roughly 14% below the 52-week high of $166.21 and well above the 52-week low of $135.63.
Fundamentals don’t justify the weakness. Q3 FY2026, filed April 24, 2026, delivered Core EPS of $1.59 against a $1.55 consensus, with revenue of $21.23 billion, up 7.4% YoY. Beauty grew 7% organic, and every segment posted growth. CEO Shailesh Jejurikar said the quarter showed “a solid acceleration in top-line results… broad-based growth across product categories and regions.” That marks five consecutive earnings beats.
The Case for $175+
The bull case is credible. Our model’s bull scenario points to $174.78 by May 2027, a 22.87% total return. Drivers include the Portfolio, Supply Chain and Productivity Plan targeting up to 7,000 non-manufacturing role reductions by end of FY2027, plus a Supply Chain 3.0 program aimed at $1.5 billion in cost-of-goods-sold savings. Innovation in synthetic biology, premium Skin Care mix, and emerging-market penetration in India, MEA, and Greater China underpin the multi-year story.